CompletedPHASE1, PHASE2NCT00322049

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Studying Dengue fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
U.S. Army Medical Research and Development Command
Principal Investigator
Robert V. Gibbons, MD, MD
U.S. Army Medical Component Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS)
Intervention
Tetravalent live attenuated dengue vaccine(biological)
Enrollment
51 enrolled
Eligibility
All sexes
Timeline
2004 – 2009

Study locations (1)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00322049 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials